Myriad Genetics, Inc.

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-12-06 EST			5-day change	1st Jan Change
15.13 ^USD	-7.52%		-7.01%	-20.95%

11-20	Myriad Genetics, Inc. Announces Updates to Its Agreement with Illumina Inc	CI
11-19	Sintx Technologies, Inc. Appoints Gregg R. Honigblum as Chief Strategy Officer	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Myriad Genetics, Inc.

Myriad Genetics, Inc. Announces Updates to Its Agreement with Illumina Inc	11-20	CI
Sintx Technologies, Inc. Appoints Gregg R. Honigblum as Chief Strategy Officer	11-19	CI
Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	11-18	MT
Myriad Genetics Says Fetal Gender Test Available at Over 8,000 Stores in US	11-13	MT
Myriad Genetics, Inc. Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch	11-13	CI
(MYGN) MYRIAD GENETICS Forecasts Fiscal Year 2024 EPS Range $0.12 - $0.14	11-07	MT
Earnings Flash (MYGN) MYRIAD GENETICS Posts Q3 EPS $0.06	11-07	MT
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q3 Revenue $213M	11-07	MT
Myriad Genetics, Inc., Q3 2024 Earnings Call, Nov 07, 2024	11-07
Myriad Genetics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024	11-07	CI
Myriad Genetics, Inc. Revises Earnings Guidance for the Year 2024	11-07	CI
Myriad Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-07	CI
Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight	11-04	DJ
Myriad Genetics Disputes Inclusion of GeneSight in UnitedHealthcare's Coverage Restriction	11-04	MT
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration	10-15	CI
Myriad Genetics, Inc. - Analyst/Investor Day	10-09
Myriad Genetics, Inc. Provides Earnings Guidance for the Third Quarter 2024 and Reaffirms Earnings Guidance for the Full-Year 2024	10-09	CI
Myriad Genetics Outlines Five Projects on Studying Breast Cancer Test	10-08	MT
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer	10-08	CI
Myriad Genetics, Ultima Genomics Collaborate to Explore UG 100 Sequencing Platform	10-03	MT
Myriad Genetics, Inc. and Ultima Genomics, Inc. Announce Joint Effort to Explore UG 100 Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics	10-03	CI
Myriad Genetics Gets Third Patent for Molecular Residual Disease Assay	10-01	MT
Myriad Genetics Has Many Opportunities for Growth, Needs Sustained Execution, Morgan Stanley Says	09-19	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	09-19	MT
Morgan Stanley Initiates Myriad Genetics at Equalweight	09-19	MT

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

2025-03-03 - Q4 2024 Earnings Release (Projected)

More about the company